Jamie Dimon is one of the highest-profile bankers in the world. Like Warren Buffett, David Solomon, or other Wall Street ...

AbbVie ABBV has built a substantial oncology franchise in recent years. Initially anchored by blood cancer drugs Imbruvica ...

These Goldman Sachs stock picks are poised for growth in 2026 and will continue to pay and raise their significant and ...

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in ...

The pharmaceutical company has also earned approval for Wegovy in treating metabolic dysfunction-associated steatohepatitis ...

Merck MRK is facing persistent challenges for its second-largest product, Gardasil, which is a vaccine for the prevention of ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

Forget the wealthy. Why this value manager is betting on average Americans, and the stocks he's buying now. When stocks start to crumble, Smead Capital Management's Bill Smead says investors need to ...

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...

Merck & Co., Inc. finds itself at a pivotal point as recent events stir the pot in the pharmaceutical landscape. With the ...

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Merck & Co., Inc.

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an ...